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In the early 1980s, more than 50% of persons with
haemophilia became infected with human immuno-
deficiency virus (HIV). This high rate of infectivity
was in large part because of the initially limited
reaction to the possibility and implications of HIV
transmission through blood and blood therapies.
Significant morbidity and mortality were the result of
this tragically inadequate response. While the risks of
HIV transmission are now well documented,
clinicians must be aware of the potential for new
pathogens.
This supplement is a synthesis of the proceedings
of an interdisciplinary symposium convened in
August 2005 at Sydney, Australia. The symposium,
part of the XXth Congress of the International
Society on Thrombosis and Haemostasis, was
designed to provide a unique perspective on the state
of emerging pathogens and to review proactive
measures to prevent their transmission in patients
with haemophilia.
New, reemerging or drug-resistant pathogens con-
tinue to arise worldwide, and their presence presents
an ongoing threat to the blood supply. Recent years
have produced outbreaks of severe acute respiratory
syndrome (SARS), West Nile virus (WNV) and avian
influenzas. In his article, Dr Michael Tapper puts
forth the basic definition of an emerging pathogen
agreed upon by the medical and scientific communi-
ties. Using the examples of WNV, SARS and avian
flu, he outlines the factors that contribute to the
emergence of these pathogens, including microbial
adaptation, global travel and human demographics.
Non-viral disease-causing agents, such as the
prions that cause variant Creutzfeldt–Jacob disease
(vCJD), also pose a real and significant threat to
blood and blood-derived therapies, as exemplified by
the recent experience in the UK. Dr James Ironside’s
article reviews the clinical and management charac-
teristics of vCJD with an emphasis on the risks of
disease transmission. He describes the three classes of
prion diseases: idiopathic (also known as sporadic),
inherited and acquired (the classification for variant
CJD). In addition, Dr Ironside reviews the epidemi-
ological considerations, including the theoretical role
of genetics in vCJD susceptibility, the potential risks
of transmission through blood and blood products
and the trends in and extent of its spread to date.
In his article, Dr Gerry Dolan shares the clinician’s
perspective on the indirect clinical and psychological
impact that vCJD may potentially have on patients
with haemophilia in the UK, primarily as a result of
new recommendations and policies to safeguard
patients from transfusion-transmitted infections.
Often developed in concert with governmental and
non-governmental agencies, these policies describe
how to inform and manage patients who may have
been exposed to vCJD through the use of UK-based
plasma concentrates, and therefore may pose a risk
for human-to-human transmission. Unfortunately,
these policies could have unintended consequences
for the haemophilia population: potential stigmat-
isation and interference with necessary medical and
surgical care. The emergence of vCJD argues for the
utmost caution in the treatment of persons with
haemophilia, both medically and sociopolitically.
By their very nature, unknown emerging patho-
gens will always cause uncertainty within the med-
ical and scientific communities, but as evidenced by
the HIV crisis of the 1980s, hesitation in the face of
theoretical risks can result in increased morbidity
and mortality. My article describes the importance of
both anticipating the potential risks which emerging
pathogens may pose to patients with haemophilia,
and discussing these risks, as well as the relative
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merits of available therapies with patients. Practi-
tioners must understand the real and theoretical risks
to their patients with haemophilia and be able to
address those fears and anxieties appropriately. I
review the basic information to know when
discussing emerging pathogens with a haemophilia
patient. While it is likely that emerging pathogens
will always be with us, they represent an opportunity
for an open and frank discussion between practi-
tioner and patient regarding optimal therapy for this
disease and other bleeding disorders.
A synthesis of a question and answer session about
emerging pathogens, patient management, vCJD and
the impact of vCJD within the haemophilia commu-
nity follows these four articles. The contents of this
supplement contain the most current information on
identified and potential infectious disease risks, their
mechanisms for emergence, and their associated
threat to the safety of the blood supply worldwide.
A special emphasis is placed on the impact of
emerging infectious diseases on clinical practice in
haemophilia. A thorough grasp of this information
enables clinicians to proactively review therapeutic
regimens with their haemophilia patients in order to
minimize anxiety with regard to emerging infec-
tious disease, counsel them on the current safety
of plasma-derived therapies and recommend a phar-
macological course of therapy that will result in the
most optimal outcomes possible.
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